Khadga Raj Aran | Pharmacology | Young Scientist Award

Khadga Raj Aran | Pharmacology | Young Scientist Award 

Research Scientist at ISF College of Pharmacy, Moga, India.

Dr. Khadga Raj Aran is a distinguished researcher in neuropharmacology, currently serving as an Associate Professor at ISF College of Pharmacy, Punjab, India. With a deep commitment to understanding the intricacies of neurological diseases, his work is largely focused on exploring neuroprotective therapies and pharmacological interventions. Dr. Aran has garnered several awards and international grants, reflecting his expertise and influence in his field. His contributions extend beyond academia to practical research applications, particularly in experimental pharmacology. Known for his dedication and innovative approach, Dr. Aran’s work has been presented at numerous global conferences, earning him significant recognition. His commitment to pharmacology research is demonstrated by his extensive hands-on skills in animal handling, sophisticated data analysis, and a keen interest in advancing neuropharmacological studies, especially those addressing neurodegenerative diseases. Dr. Aran’s career reflects both an impressive academic journey and a noteworthy dedication to impactful scientific discovery.

Profile

Scopus

Education

Dr. Khadga Raj Aran’s academic journey is marked by a strong foundation in pharmacology and neuropharmacology. He completed his Ph.D. in Pharmacology at the ISF College of Pharmacy, where he achieved a distinction with a high CPI score of 8.93. His research focused on neuroprotective agents against drug-induced neurological damage, which has become the foundation of his career. Prior to this, he earned his M.Pharm in Pharmacology, also with distinction, from the same institution. He holds a B.Pharm degree from East West College of Pharmacy under Rajiv Gandhi University of Health Sciences, Karnataka, where he graduated with honors. This comprehensive academic background has equipped Dr. Aran with a deep knowledge base and the technical skills necessary to excel in his research, making him a well-rounded expert in pharmacology with a keen specialization in neuropharmacology.

Professional Experience

Dr. Aran has accumulated a wealth of experience in pharmacology research and education. He currently holds the position of Associate Professor in the Department of Pharmacology at ISF College of Pharmacy. Previously, he worked as a Senior Research Fellow (SRF) funded by the Indian Council of Medical Research, where he honed his skills in handling complex neuropharmacological research. His early career included a Junior Research Fellowship at Sanjay Gandhi Postgraduate Institute of Medical Sciences. Dr. Aran’s research experience is diverse, encompassing animal handling, various laboratory techniques, and software proficiency for data analysis. His academic role allows him to mentor young scientists, while his research focuses on experimental neurology and pharmacology. Dr. Aran’s dedication and expertise have enabled him to contribute significantly to scientific understanding in these areas, presenting him as a thought leader in his field.

Research Interests

Dr. Aran’s research interests lie at the intersection of pharmacology and neuroscience, with a particular focus on neuroprotection and neurodegenerative diseases. His work explores therapeutic strategies for mitigating the harmful effects of pharmaceutical compounds on the brain, specifically targeting diseases like Parkinson’s and Alzheimer’s. Driven by a desire to contribute solutions to these critical health challenges, Dr. Aran investigates neuropharmacological agents and molecular pathways that could pave the way for new treatments. His research often utilizes advanced animal models and bioassays to study neurological responses, aiming to develop safer, more effective therapeutic options. This focus on neuroprotective pharmacology is fueled by a commitment to advancing public health and deepening scientific understanding of brain function and resilience.

Research Skills

Dr. Aran brings a comprehensive skill set to his neuropharmacology research. He has extensive experience in animal handling techniques across various species, such as rats, mice, and guinea pigs, which he employs for in-depth neurological studies. His proficiency extends to sophisticated laboratory techniques, including ELISA, HPLC-ECD, and stereotaxic surgeries, as well as blood collection and drug administration methods. Dr. Aran is skilled in using software such as GraphPad Prism, EndNote, and ChemDraw for data analysis and documentation, and he utilizes Photoshop and CorelDraw for diagrammatic representations. His research toolkit is completed by a solid command of statistical software like SPSS, enabling him to conduct rigorous data analysis and produce reliable results. These advanced research skills highlight his capability to conduct complex pharmacological studies with precision and accuracy.

Awards and Honors

Throughout his career, Dr. Khadga Raj Aran has received numerous accolades for his scientific contributions and research excellence. Among his prestigious achievements is a best design patent awarded by the Government of India, reflecting his innovative approach to pharmacological research. Dr. Aran has also been recognized internationally, receiving the Best Scholar Award from the International Scientist Awards for his contributions to Engineering, Science, and Medicine. His exceptional review work for the International Journal of Biochemistry Research and Review earned him a Certificate of Excellence in Reviewing. He has further demonstrated his scholarly impact through multiple travel grants for presenting research abroad, including grants from the IBRO and MDS International Congress. Each of these honors underscores Dr. Aran’s dedication to advancing pharmacology, establishing him as a leading figure in neuropharmacology research.

Conclusion:

Dr. Khadga Raj Aran is a strong candidate for the Research for Young Scientist Award due to his solid educational background, research experience, and contributions to neuropharmacology. His achievements, including travel grants, conference awards, and active involvement in national and international research organizations, underscore his potential to make significant contributions to the field. With continued research and collaboration efforts, Dr. Aran has the potential to achieve greater recognition and impact within the scientific community, making him a deserving recipient of the award.

Publications Top Notes

“Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders”
Authors: Bala, K., Porel, P., Aran, K.R.
Year: 2024
Journal: Psychopharmacology, Volume 241, Issue 10, Pages 1939–1954
Citations: 0

“Lansoprazole induces hippocampal cell apoptosis and impairs learning and memory functions via activation of tau phosphorylation and Aβ (1–42) pathway in adult rats”
Authors: Aran, K.R., Gupta, G.D., Singh, S.
Year: 2024
Journal: Toxicology and Environmental Health Sciences
Citations: 0

“Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease–A step towards mitochondria based therapeutic strategies”
Authors: Aran, K.R., Singh, S.
Year: 2023
Journal: Aging and Health Research, Volume 3, Issue 4, Article 100169
Citations: 2

“Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats”
Authors: Aran, K., Gupta, G., Singh, S.
Year: 2023
Journal: Asian Pacific Journal of Tropical Biomedicine, Volume 13, Issue 7, Pages 296–305
Citations: 0

“Amelioration of Cognitive Deficit by Cryptotanshinone in a Long-term Utilisation of Proton Pump Inhibitor-Induced Alzheimer’s Disease-Like Condition in a Rat Model”
Authors: Aran, K.R., Das Gupta, G., Singh, S.
Year: 2023
Journal: Revista Brasileira de Farmacognosia, Volume 33, Issue 3, Pages 595–609
Citations: 2

Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

Prof Dr. Ronit Satchi-Fainaro | Pharmacology | Outstanding Scientist Award

 Cancer Biology Research Center at Tel Aviv University, Israel

Ronit Satchi-Fainaro is a prominent figure in cancer research, currently serving as a Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and Director of the Cancer Biology Research Center. With a Ph.D. in polymer chemistry and extensive postdoctoral training at renowned institutions, her research focuses on cancer biology, tumor dormancy, and the development of targeted nanomedicines. Satchi-Fainaro has pioneered multi-modality polymer therapeutics that combine anti-angiogenic agents with chemotherapeutics, significantly advancing the field of cancer treatment. Her impressive publication record includes groundbreaking articles in Nature Medicine and Cancer Cell, and she has filed multiple patents for her innovative findings. Additionally, she has received numerous accolades for her contributions to science, including the Humboldt Foundation Bessel Research Prize. Satchi-Fainaro’s leadership in interdisciplinary research and commitment to translating scientific discoveries into clinical applications make her a leading voice in modern cancer therapeutics.

Professional Profile

Education

Ronit Satchi-Fainaro has an impressive educational background that laid the foundation for her distinguished career in pharmacology and cancer research. She earned her Bachelor of Pharmacy (B.Pharm.) degree in Pharmacology from The Hebrew University, Faculty of Medicine, School of Pharmacy, in June 1995. Following her undergraduate studies, she completed an internship in Industrial Pharmacy at Perio Products Ltd. in Jerusalem in March 1996. Satchi-Fainaro then pursued her Ph.D. at the University of London, specializing in polymer chemistry, biochemistry, and cancer nanomedicine. Her doctoral research, titled “PDEPT: Polymer Directed Enzyme Prodrug Therapy,” was completed in November 1999 under the supervision of Prof. Ruth Duncan. Subsequently, she expanded her expertise through postdoctoral fellowships at Tel Aviv University and Harvard Medical School, focusing on tumor biology, molecular biology, and protein delivery, further solidifying her status as a leader in the field of cancer research and nanomedicine.

 

Professional Experience

Ronit Satchi-Fainaro is a distinguished Full Professor in the Department of Physiology and Pharmacology at Tel Aviv University and serves as the Director of the Cancer Biology Research Center. With over 15 years of leadership at the university, she has spearheaded a multidisciplinary research group focused on innovative cancer therapies. Satchi-Fainaro’s expertise encompasses polymer chemistry, biochemistry, and nanomedicine, leading to the development of targeted polymer therapeutics and nano-vaccines. She has collaborated with prominent institutions, including Harvard Medical School, where she contributed to significant advances in tumor biology and angiogenesis. Her entrepreneurial spirit is evident through her co-founding of biotech companies, such as ImmuNovation, Ltd., and her active role on various scientific advisory boards. Satchi-Fainaro has garnered numerous accolades, including the Humboldt Foundation Bessel Research Prize, reflecting her substantial impact in cancer research and drug delivery systems. Her work continues to push the boundaries of personalized medicine and cancer therapeutics

Research Interests

Ronit Satchi-Fainaro’s research interests lie at the intersection of cancer biology, pharmacology, and nanomedicine. She focuses on understanding the mechanisms underlying cancer dormancy and the tumor-host interactions that facilitate metastasis. Her innovative work involves developing targeted nanomedicines that integrate anti-stromal agents with chemotherapeutics to enhance treatment efficacy while reducing toxicity. Satchi-Fainaro’s laboratory employs advanced techniques such as molecular imaging, 3D bioprinted cancer models, and personalized theranostics to investigate tumor biology and angiogenesis. She aims to identify molecular signatures that predict tumor behavior and survivorship, driving the rational design of novel therapeutic approaches. Additionally, her interdisciplinary approach combines elements of biology, chemistry, engineering, and material sciences, facilitating the development of highly selective drug delivery systems. Through her pioneering research, Satchi-Fainaro aspires to contribute to more effective cancer therapies and improve patient outcomes in the fight against cancer.

Ronit Satchi-Fainaro has received numerous prestigious awards and honors throughout her distinguished career, reflecting her significant contributions to cancer research and nanomedicine. Notable accolades include the British Council Chevening Award, the Nagai Foundation Graduate Student Award, and the Fulbright Scholarship. She was recognized as a “Person of the Year” in Medicine by Forbes Israel and included in various influential lists, such as the “50 Most Influential Women” and “40 Under 40” by prominent Israeli journals. In addition, she has received the ERC Advanced Grant, the 3D Printing Industry Award for Medical Application of the Year, and the Bessel Research Prize from the Humboldt Foundation. Her work has garnered multiple research prizes for exceptional publications at Tel Aviv University and recognition as a Fellow of the American Institute of Medical and Biological Engineers (AIMBE). These accolades highlight her impactful research and leadership in advancing innovative cancer therapies.

 

Conclusion

Ronit Satchi-Fainaro is a distinguished leader in cancer research, whose innovative work in nanomedicine has significantly advanced the understanding and treatment of cancer. With a robust academic background and over 15 years at Tel Aviv University, she has successfully led multidisciplinary research initiatives that tackle complex questions in tumor biology and drug delivery. Her pioneering development of multi-modality targeted nanomedicines has not only garnered numerous patents but also positioned her at the forefront of translational research. Satchi-Fainaro’s impressive publication record in high-impact journals, coupled with her numerous accolades—including the Humboldt Foundation Bessel Research Prize—underscores her contributions to science. As the Director of the Cancer Biology Research Center, she exemplifies a commitment to fostering collaboration and mentorship in the scientific community. Overall, her accomplishments and dedication to improving cancer therapies make her a highly deserving candidate for the Research for Outstanding Scientist Award.

 

Publication top noted
  • Title: interFLOW: maximum flow framework for the identification of factors mediating the signaling convergence of multiple receptors
    Authors: Sheinin, R., Salomon, K., Yeini, E., Sharan, R., Madi, A.
    Year: 2024
    Citations: 0
  • Title: Polyester nanoparticles delivering chemotherapeutics: Learning from the past and looking to the future to enhance their clinical impact in tumor therapy
    Authors: Longobardi, G., Moore, T.L., Conte, C., Satchi-Fainaro, R., Quaglia, F.
    Year: 2024
    Citations: 0
  • Title: Multifunctional Nanovaccine Sensitizes Breast Cancer to Immune Checkpoint Therapy
    Authors: Peres, C., Matos, A.I., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2024
    Citations: 2
  • Title: Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity
    Authors: Monteran, L., Ershaid, N., Scharff, Y., Zhang, X.H.-F., Erez, N.
    Year: 2024
    Citations: 3
  • Title: The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine
    Authors: Pozzi, S., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker
    Authors: Liubomirski, Y., Tiram, G., Scomparin, A., Shabat, D., Satchi-Fainaro, R.
    Year: 2024
    Citations: 3
  • Title: Intranasal Multiepitope PD-L1-siRNA-Based Nanovaccine: The Next-Gen COVID-19 Immunotherapy
    Authors: Acúrcio, R.C., Kleiner, R., Vaskovich-Koubi, D., Florindo, H.F., Satchi-Fainaro, R.
    Year: 2024
    Citations: 0
  • Title: Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors
    Authors: Matos, A.I., Peres, C., Carreira, B., Satchi-Fainaro, R., Florindo, H.F.
    Year: 2023
    Citations: 6
  • Title: Deoxyhypusine hydroxylase: A novel therapeutic target differentially expressed in short-term vs long-term survivors of glioblastoma
    Authors: Ofek, P., Yeini, E., Arad, G., Geiger, T., Satchi-Fainaro, R.
    Year: 2023
    Citations: 4
  • Title: Development of Chitosan Particles Loaded with siRNA for Cystatin C to Control Intracellular Drug-Resistant Mycobacterium tuberculosis
    Authors: Pires, D., Mandal, M., Matos, A.I., Florindo, H.F., Anes, E.
    Year: 2023
    Citations: 6

Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Assist Prof Dr. Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Assistant Professor, EDA, Egypt

With a solid foundation in pharmacy, including a Bachelor’s, Master’s, and PhD from Cairo University, and a position as Associate Professor, this individual demonstrates exceptional expertise. Their diverse professional experience spans quality control, management, and academic roles, showcasing their leadership and practical knowledge in the pharmaceutical field. Their prolific research output includes numerous publications on advanced drug delivery systems and nanotechnology, reflecting significant contributions to pharmaceutical sciences. Active participation in various training courses, workshops, and international conferences highlights their commitment to continuous professional development. Additionally, their multilingual skills enhance their ability to collaborate in diverse settings. Overall, their comprehensive background in education, research, and professional development, combined with their active engagement in the scientific community, makes them a highly suitable candidate for the Best Researcher Award.

Education

The candidate has a robust educational background that serves as the foundation of their expertise in the field of pharmaceutical sciences. They earned a Bachelor of Pharmacy degree from Cairo University in 1996, graduating with honors, which set the stage for their academic and professional journey. Their pursuit of advanced knowledge led them to complete a Master’s degree in Pharmaceutics in 2007 and later a PhD in 2011, both from the same esteemed institution. This rigorous academic training has equipped them with in-depth knowledge of pharmaceutics, drug formulation, and pharmaceutical analysis. In 2019, they further solidified their academic credentials by attaining the position of Associate Professor, demonstrating their commitment to education, research, and mentorship. Their continuous academic progression reflects a strong commitment to excellence and a desire to contribute significantly to the pharmaceutical sciences, positioning them as a thought leader in their field and a prime candidate for the Best Researcher Award.

Profesional Experience

The candidate has an extensive professional background in the pharmaceutical sector, beginning their career as a QC analyst for raw materials at NODCAR from 1996 to 1999. They then transitioned to academia as a teaching assistant at the Faculty of Pharmacy, October University, in 1999. Between 2000 and 2012, they worked as a QC analyst specializing in physical properties before moving into management roles, including quality manager and deputy lab manager. From 2016 to 2021, they served as a technical manager, demonstrating their expertise in overseeing laboratory operations and maintaining quality standards. Their role expanded further as they joined several committees, contributing to updating pharmaceutical guidelines and developing the Egyptian pharmacopeia. In 2021, they became the lab manager of the physicochemical lab at the Egyptian Drug Authority (EDA), where they continue to lead and innovate in quality control and research.

Research Skill

The candidate possesses exceptional research skills, demonstrated through a prolific publication record in high-impact journals and extensive experience in developing innovative pharmaceutical formulations. They have expertise in designing and conducting complex experimental studies, including the use of advanced methodologies like Box–Behnken design for optimization and in vivo evaluations. Their research work spans various domains, including nanotechnology, ocular drug delivery, and gastroretentive systems, showcasing versatility and a strong ability to adapt to emerging scientific trends. Additionally, their role in supervising master’s and PhD theses highlights their leadership in guiding future researchers. The candidate is also well-versed in utilizing statistical analysis tools and quality-by-design approaches, which are critical for ensuring the rigor and reliability of research findings. Their ability to translate research into practical applications, coupled with active participation in committees that shape pharmaceutical guidelines, underscores a profound impact on both academic and industry standards in the pharmaceutical sciences.

Awards And Recoginition

The individual has received multiple accolades throughout their career, reflecting their outstanding contributions to the field of pharmaceutical sciences. Their expertise in pharmaceutics and dedication to research have been recognized by esteemed institutions and professional bodies. Notably, they have been honored for their innovative work in drug delivery systems and quality management, which have had a significant impact on the pharmaceutical industry. They have been a valuable member of committees responsible for updating pharmaceutical guidelines and establishing national standards, further highlighting their influence and leadership in the field. Additionally, their research publications in renowned international journals have been widely cited, earning them recognition among peers as a leading researcher. Their participation in prestigious conferences and workshops, both as a presenter and a participant, underscores their commitment to continuous learning and sharing knowledge. These recognitions affirm their position as a distinguished professional dedicated to advancing pharmaceutical science and improving healthcare outcomes.

Conclution

The individual’s blend of academic excellence, practical experience, prolific research output, and continuous professional growth makes them a highly suitable candidate for the Best Researcher Award. Their achievements reflect their dedication to advancing pharmaceutical science and their impact on the field.

Publication Top Notes

  1. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency
    • Authors: Nagham H. Kamal, Fatema R. Saber, Abeer Salama, Dalia M. N. Abouhussein, Soha Ismail, Hala M. El-Hefnawy, Meselhy R. Meselhy
    • Year: 2024
    • Citation: Kamal NH, Saber FR, Salama A, Abouhussein DMN, Ismail S, El-Hefnawy HM, Meselhy MR. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency. Future Journal of Pharmaceutical Sciences. 2024 Aug 19. doi:10.1186/s43094-024-00678-2.
  2. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment
    • Authors: Abeer Khattab, Soha Ismail, Areeg M. Abd-Elrazek
    • Year: 2024
    • Citation: Khattab A, Ismail S, Abd-Elrazek AM. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment. AAPS PharmSciTech. 2024 Jun 27. doi:10.1208/s12249-024-02852-4.
  3. Optimization of topical curcumin spanlastics for melanoma treatment
    • Authors: Soha Ismail, Doaa Garhy, Howida K. Ibrahim
    • Year: 2023
    • Citation: Ismail S, Garhy D, Ibrahim HK. Optimization of topical curcumin spanlastics for melanoma treatment. Pharmaceutical Development and Technology. 2023 May 28. doi:10.1080/10837450.2023.2204926.
  4. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation
    • Authors: Marwa H. Shukr, Soha Ismail, Ghada G. El-Hossary, Amany H. El-Shazly
    • Year: 2022
    • Citation: Shukr MH, Ismail S, El-Hossary GG, El-Shazly AH. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation. Journal of Liposome Research. 2022 Oct 2. doi:10.1080/08982104.2022.2025828.
  5. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI
    • Authors: Marwa Farrag Abd El-Aziz, Soha Ismail, Mina Ibrahim Tadros, Mohamed Ahmed Elnabarawi
    • Year: 2020
    • Citation: Abd El-Aziz MF, Ismail S, Tadros MI, Elnabarawi MA. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI. Pharmaceutical Development and Technology. 2020 May 27. doi:10.1080/10837450.2020.1720235.
  6. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
    • Authors: Marwa H. Shukr, Soha Ismail, Samya Mahmoud Ahmed
    • Year: 2019
    • Citation: Shukr MH, Ismail S, Ahmed SM. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity. Journal of Drug Delivery Science and Technology. 2019 Feb. doi:10.1016/j.jddst.2018.12.001.
  7. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy
    • Authors: Dalia S. Shaker, Soha Ismail, Selwan Hamed, Eman M. El-Shishtawy
    • Year: 2018
    • Citation: Shaker DS, Ismail S, Hamed S, El-Shishtawy EM. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy. Journal of Drug Delivery Science and Technology. 2018 Dec. doi:10.1016/j.jddst.2018.09